HDAC9 and glioma: In alignment with this observation, we found that the TRAP1 inhibitor, gamitrinib, enhanced the anti-glioma effects of HDAC inhibitors both in vitro and in vivo, which occurred in part through enhanced activation of a cell death with features of intrinsic apoptosis [17].